Please login to the form below

Not currently logged in
Email:
Password:

TS23

This page shows the latest TS23 news and features for those working in and with pharma, biotech and healthcare.

Daiichi Sankyo licenses clot-busting antibody

Daiichi Sankyo licenses clot-busting antibody

The drug candidate - called TS23 - is in phase I trials but has shown "exceptional efficacy and safety in multiple disease models", according to Memphis-based Translational Sciences. ... It will pay Translational Sciences unspecified fees, milestones and

Latest news

More from news
Approximately 1 fully matching, plus 0 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Dovetail

We’re a specialist health consultancy that supports companies, healthcare professionals and patients to work hand in hand with a common...

Latest intelligence

The Patient Will See You Now – The Evolution of the Doctor-Patient Relationship
The doctor-patient relationship is an ever changing one that changes as society changes. Technology then helps to drive this change along with a wide number of other factors....
Mind the Gap – Challenging Immunisation Apathy and Misinformation
world, the biggest challenges remain apathy and misinformation. Since a measles vaccine was introduced in the UK in 1968, Public Health England estimates that 20 million measles cases and 4,500...
Towards Better HCP Engagement – An Email Masterclass
6% of HCPs prefer being contacted by email, compared to 17% who favour the second most popular option: direct interaction with reps....